In the subgroup analysis, similar HR values for disease recurrence or mortality were observed for tumor-cell PD-L1 expression ≥1% (HR 0.75) and <1% (HR, 0.73), indicating that the efficacy of adjuvant nivolumab treatment was independent of PD-L1 expression levels (92). This evidence concerns the gene CD274 and neoplasm.